Applying proteomic technology to clinical virology.

C. Mancone (1, 2) , F. Ciccosanti (1) , C. Montaldo (1, 2) , A. B. Perdomo (1) , M. Piacentini (1, 3) , T. Alonzi (1) , G. M. Fimia (1) , M. Tripodi (1, 2)

1 National Institute for Infectious Diseases L. Spallanzani
2 Department of Cellular Biotechnologies and Haematology
3 University of Rome "Tor Vergeta"

Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few decades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus making a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic composition and localization of the protein platforms involved in various host-virus interactions. Among the different possible approaches, mass spectrometry-based proteomics is increasingly being used to define the protein composition in subcellular compartments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational modifications. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and pathogenicity, with a particular focus on recent advances in hepatitis C research.

Domaines: Sciences du Vivant [q-bio]; Génomique, Transcriptomique et Protéomique [q-bio.GN]; Pharmacologie

C. Mancone, F. Ciccosanti, C. Montaldo, A. B. Perdomo, M. Piacentini, et al.. Applying proteomic technology to clinical virology.. Clinical Microbiology and Infection, 2013, 19 (1), pp.23-8. ⟨10.1111/1469-0691.12029⟩. ⟨pasteur-01053520⟩